Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 90% Improvement Relative Risk ICU admission 72% Discharge 80% Time to viral- 59% c19ivermectin.com Akhtar et al. Ivermectin for COVID-19 LATE TREATMENT Favors ivermectin Favors control
Akhtar, 423 patient ivermectin late treatment study: 90% lower mortality [p<0.0001], 72% lower ICU admission [p=0.0006], 80% higher hospital discharge [p<0.0001], and 59% faster viral clearance [p<0.0001] https://c19p.org/akhtar
copied to clipboard
Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study.
Akhtar et al., The Professional Medical Journal, doi:10.29309/TPMJ/2022.29.09.6634
1 Sep 2022    Source   PDF   Share   Tweet
Retrospective 423 patients in Pakistan, 216 receiving 6 day treatment, showing lower mortality, lower ICU admission, and faster viral clearance with treatment. Limited baseline information per group is provided. There were more severe patients in the ivermectin group. Logistic regression results are mentioned without full details. The difference in mortality was not statistically significant in logistic regression.
risk of death, 90.4% lower, RR 0.10, p < 0.001, treatment 2 of 216 (0.9%), control 20 of 207 (9.7%), NNT 11.
risk of ICU admission, 71.6% lower, RR 0.28, p < 0.001, treatment 8 of 216 (3.7%), control 27 of 207 (13.0%), NNT 11.
risk of no hospital discharge, 79.6% lower, RR 0.20, p < 0.001, treatment 10 of 216 (4.6%), control 47 of 207 (22.7%), NNT 5.5.
time to viral-, 58.8% lower, relative time 0.41, p < 0.001, treatment mean 8.39 (±2.04) n=216, control mean 20.38 (±6.32) n=207.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in meta analysis: pending additional information from authors.
Akhtar et al., 1 Sep 2022, retrospective, Pakistan, peer-reviewed, mean age 51.9, 9 authors, dosage 12mg days 1-6.
Contact: umarraza028@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit